FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAlaunos Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
Back to Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. (TCRT) analyst ratings and price targets

The latest rating and price-target changes from Wall Street analysts, newest first — the firm, the analyst, and the article each one was published in.

Consensus Hold (10 analysts)

Firm · analystDateRatingPrice targetSource
HC Wainwright & Co.Aug 15, 2023DowngradeBuy → Neutral——
Laidlaw & Co.Aug 14, 2023DowngradeBuy → Hold——
HC Wainwright & Co.May 14, 2023UpgradeNeutral → Buy——
Wells FargoMay 3, 2022UpgradeEqual Weight → Overweight——
Raymond JamesNov 8, 2021MaintainsMarket Perform——
Raymond JamesAug 9, 2021DowngradeOutperform → Market Perform——
Raymond JamesMay 6, 2021MaintainsOutperform——
JefferiesMar 11, 2021DowngradeBuy → Hold——
HC Wainwright & Co.Feb 28, 2021DowngradeBuy → Neutral——
Raymond JamesMar 2, 2020MaintainsOutperform——
Raymond JamesNov 14, 2018UpgradeMarket Perform → Outperform——
JP MorganJun 17, 2018DowngradeNeutral → Underweight——
Wells FargoAug 9, 2016UpgradeUnderperform → Market Perform——
BMO CapitalJun 21, 2015DowngradeOutperform → Market Perform——
MizuhoMar 9, 2015DowngradeBuy → Neutral——

Source: Wall Street analysts' published price targets and ratings, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.